DECART

DeCART Therapeutics is a biotechnology company founded by a team of scientific and business leaders including Carl H. June, M.D., Joseph A. Fraietta, Ph.D., Xianxin Hua, M.D., Ph.D., and Dana M. Hammill, M.S., M.B.A., from the University of Pennsylvania, and Arthur T. Sands, M.D., Ph.D. and Pierre Beaurang, Ph.D. from Nurix Therapeutics... Enhancing CAR T cells through targeted protein modulation is the scientific foundation of DeCART. Our goal is to modify underlying CAR T biology ex vivo and in vivo through small molecule pharmacologic control of protein levels. Our ultimate goal is to improve CAR T therapies and outcomes for cancer patients.

Also known as: DeCART Therapeutics, DeCART Therapeutics, Inc.

Primary location: San Francisco United States